Last reviewed · How we verify
continuous oral cyclophosphamide and methotrexate
At a glance
| Generic name | continuous oral cyclophosphamide and methotrexate |
|---|---|
| Sponsor | Grupo de Apoio ao Adolescente e a Crianca com Cancer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion (EARLY_PHASE1)
- CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (PHASE1)
- CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL (PHASE1, PHASE2)
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (PHASE1, PHASE2)
- Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma (PHASE3)
- Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma (PHASE2)
- BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer (PHASE2)
- Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: